Zoetis (ZTS) Stock

The Wall Street Journal published an article stating that Zoetis' OA pain medication, Librela, is unsafe. I discuss these claims and share my reasons for thinking they are not valid. Although Librela may soon have a change in its label, I believe there is no cause for concern, and I explain my reasoning.

Zoetis (ZTS) finished the last trading day at $164.84, which is an increase of 0.81% compared to the day before.

Two companies that match this description are Idexx Laboratories (NASDAQ: IDXX) and Zoetis (NYSE: ZTS), both of which specialize in animal healthcare. Idexx is already a key investment for my daughter, while Zoetis is one of my own, and I believe that gradually increasing your investment in successful companies is a smart strategy, as suggested by David Gardner, co-founder of Motley Fool. Although Idexx and Zoetis have dropped 37% and 28% from their highest values, they have still outperformed the S&P 500 in total returns over the last ten years.

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.

Kristin Peck, the CEO of Zoetis, discusses the worries that pet owners have about taking care of their cherished pets on 'The Claman Countdown.'

Zoetis operates in several areas that are projected to grow at a rate of 4% or higher. The company is seeing increasing revenues, has a solid financial position, a high free cash flow margin, and no significant debts coming due. Products like Librela, Solensia, and Simparica Trio are expected to boost the stock in the future.

Zoetis Inc. (NYSE:ZTS) will be presenting at the Jefferies London Healthcare Conference on November 20, 2024, at 10:00 AM ET. The company's CFO, Wetteny Joseph, will be participating in the call. Glen Santangelo from Jefferies expressed his gratitude for Zoetis joining the presentation.

Zoetis, a top company in animal health, has experienced remarkable growth with a 17.55% compound annual growth rate (CAGR) since going public, surpassing the S&P 500. The rise in pet ownership and spending worldwide helps the company maintain steady revenues, even during economic challenges. Additionally, Zoetis has a strong competitive advantage due to its wide range of products, solid patent protections, and ongoing investment in research and development.

PARSIPPANY, N.J.--(BUSINESS WIRE)--ZOETIS HAS NAMED JAMIE BRANNAN AS THE FIRST CHIEF COMMERCIAL OFFICER.